Skip to content

Feasibility and efficacy of peripheral nerve blockers combined with esketamine: a single-center, double-blind, randomized controlled trial

Feasibility and efficacy of peripheral nerve blockers combined with esketamine: a single-center, double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088017
Enrollment
Unknown
Registered
2024-08-09
Start date
2024-08-15
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Ropivacaine group (Group L):Group L received conventional ropivacaine nerve block anesthesia combined with general anesthesia
Esketamine Group (Group I):Group I used ketamine combined with ropivacaine nerve block anesthesia combined with general anesthesia

Sponsors

Xuzhou Renren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: BMI 18.5-35.0 kg/m2, age 18-60 years old, ASA II-III, orthopedic surgery under quasi-general anesthesia;

Exclusion criteria

Exclusion criteria: Age younger than 18 years, patient who has not quit smoking, pneumothorax or giant bullosa, history of pulmonary surgery, invasive mechanical ventilation within 30 days, pregnancy, persistent hemodynamic instability or refractory shock, severe heart disease, severe chronic obstructive pulmonary disease, moderate or severe pulmonary hypertension, moderate or severe acute respiratory distress syndrome, diagnosis of intracranial hypertension, patient participating in it other interventional studies, local anesthetic allergy, puncture site infection or coagulation dysfunction.

Design outcomes

Primary

MeasureTime frame
Visual analog scoring;Pittsburgh Sleep Quality Score;

Secondary

MeasureTime frame
Postoperative adverse reactions;Postoperative QoR-40 score;Intraoperative propofol and remifentanil dosages;

Countries

China

Contacts

Public ContactWang Kang

Xuzhou Renren Hospital

wkadis@163.com+86 139 5216 4520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026